This week's must-know community updates, latest research & events
March 13, 2025
New This Week
Exciting news! There is now a new section featuring clinical trials that are actively recruiting patients. This highly requested addition gives you direct access to cutting-edge research opportunities that could shape the future of treatment.
Stay informed about potentially life-changing studies and let us know what you think by replying to this email!
In the phase 2 BMT CTN 1902 trial discussed by Alfred L. Garfall, MD, researchers investigated the use of idecabtagene vicleucel (ide-cel) in patients with multiple myeloma who had previously undergone a stem cell transplant. The study aimed to determine the effectiveness of this CAR T-cell therapy as a consolidation treatment, which is a therapy given after the initial treatment to further reduce the number of cancer cells.
The trial's findings are significant as they explore the potential benefits of ide-cel in a post-transplant setting, which could offer a new therapeutic strategy for patients with multiple myeloma. The results could pave the way for improved outcomes by integrating advanced cellular therapies into the treatment regimen after a stem cell transplant. The specific data on response rates, duration of response, and patient outcomes from the trial were not detailed in the abstract provided by Targeted Oncology News (2025).
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
More Info 
Add to Calendar 